Moreover, by using systematic profiling of DNA methylation at CpG island promoters of pathways relevant to ovarian carcinogenesis, Dai et al. have identified the DNA methylation biomarker-PRDX2 that give rise to a methylation index capable of predicting progression free survival in ovarian cancer independently from known clinical prognostic feature [36]. This evidence concerns the gene PRDX2 and ovarian cancer.